Remove Adverse Reactions Remove Biosimilars Remove Mayo Clinic
article thumbnail

Donanemab-Azbt Receives FDA Label Update With New Dosing for Alzheimer Disease

Pharmacy Times

While no new adverse reactions were observed in this study, higher rates of hypersensitivity and infusion-related reactions were observed. Mayo Clinic. FDA approves updated label for Lilly's Kisunla (donanemab-azbt) with new dosing in early symptomatic Alzheimer's disease. Eli Lilly and Company.